VOLUME 23 NUMBER 6 JUNE 2016 nature structural & molecular biology a r t i c l e s BCL-2 family proteins regulate mitochondrial apoptosis through heterodimeric and homo-oligomeric protein interactions, which ultimately dictate whether a cell will live or die. The 'BH3-only' protein members contain a BCL-2 homology 3 (BH3) killer domain used for transmitting signals of cell stress to the multidomain pro-and antiapoptotic proteins. Engagement of multidomain proapoptotic members BAX and BAK by select BH3-only proteins, such as BID, BIM and PUMA, conformationally activates BAX and BAK, transforming them from monomeric proteins into oligomeric pores that pierce the mitochondrial outer membrane and thereby induce apoptosis 1 . Antiapoptotic proteins, such as BCL-X L and MCL-1, bind and block BH3-only and multidomain proapoptotic members, consequently preventing mitochondrial apoptosis.
behavior, as revealed by dilution binding assays (Supplementary
. A series of naphthoquinone arylsulfonimines, classic PAINs that covalently label cysteines and undergo redox cycling, inhibited the interaction between MCL-1 SAHB A and MCL-1∆N∆C with potencies that correlated with electrophilic activity ( Supplementary  Fig. 1b) . The most potent effector ( Fig. 1a and Supplementary 10 -6 10 -7 10 -8 10 -9 10 -6 10 -5 10 -6 10 -7 10 -8 10 -9 10 -10 10 -5 10 -6 10 -7 10 -8 10 -9 10 -10 10 -7 10 -8 10 a r t i c l e s npg a r t i c l e s Fig. 1b,c) retained specificity for MCL-1, as demonstrated by selective disruption of the fluorescein isothiocyanate (FITC)-BID BH3 interaction with MCL-1∆N∆C ( Fig. 1b) but not BCL-X L ∆C (Fig. 1c ) in a competitive fluorescence polarization (FP) binding assay. MS analyses confirmed small-molecule modification of MCL-1∆N∆C ( Fig. 1d ) and localized the reactivity to C286, which is found on the opposite face of the protein (N terminus of α6) from the canonical BH3-binding groove ( Fig. 1e and Supplementary Fig. 1d,e) . Given the molecule's inhibitory effect on BH3 binding activity by engaging a noncanonical interaction site, we named this compound MCL-1 allosteric inhibitor molecule 1 (MAIM1) ( Fig. 1a) .
To validate the requirement of C286 for MAIM1 activity, we performed C286S mutagenesis and found that MAIM1 was no longer capable of derivatizing MCL-1∆N∆C ( Fig. 1f) . Whereas conjugation of MAIM1 to MCL-1∆N∆C resulted in dose-responsive inhibition of FITC-BID BH3 binding activity, C286S mutagenesis markedly blunted the effect ( Fig. 2a,b) . To determine whether the molecular structure of MAIM1 contributed to the inhibitory activity, we compared the effects of MAIM1 and iodoacetamide (IAM) exposure on MCL-1∆N∆C binding activity in dilution assays. We confirmed that both compounds equally and effectively quenched C286, as measured by thiol quantification assays ( Fig. 2c) . However, only MAIM1 conjugation inhibited the FITC-BID BH3 binding capacity of MCL-1∆N∆C ( Fig. 2d,e ). Together, these data indicate that MAIM1 derivatization of C286, as opposed to simple alkylation, impairs the ability of MCL-1∆N∆C to engage the proapoptotic BID BH3 domain, thus implicating a new and indirect targeting mechanism for disarming MCL-1.
An allosteric mechanism for MAIM1 inhibition of MCL-1
How does covalent modification of C286 by MAIM1 impair the canonical BH3 binding activity of MCL-1? Given the critical role of allosteric sensing in the regulation of BCL-2 family proteins 17,18 , we explored whether MAIM1 modification of MCL-1 affected its conformation, as assessed by limited trypsin proteolysis. Indeed, we found that MAIM1-derivatized MCL-1∆N∆C, compared with the unconjugated form, underwent more rapid proteolysis and exhibited an increased diversity of degradation products ( Fig. 2f) , thus suggesting structural differences between the unmodified and MAIM1-derivatized forms of MCL-1∆N∆C.
To interrogate the mechanistic relationships among the structure of MCL-1∆N∆C, its BH3 binding capacity and the MAIM1 effect, we performed hydrogen/deuterium-exchange MS (HXMS), which effectively probes changes in peptide or protein structure by measuring deuterium incorporation of backbone amide hydrogens over time 19 . We first examined the effect of MCL-1∆N∆C interaction on the deuterium-exchange profile of a BID BH3 peptide. BID BH3 alone underwent rapid and complete deuterium exchange within 10 s of dilution into deuterium buffer ( Fig. 3) , a result consistent with its disordered structure in solution, as previously reported 20 . However, in the presence of added MCL-1∆N∆C, deuterium exchange was markedly slowed ( Fig. 3) , thus reflecting induced folding and ligand-target interaction. Indeed, hydrogen-bonding involving backbone amide hydrogens, as in α-helical peptides, or upon peptide and protein engagement, can retard or even prevent deuterium exchange [21] [22] [23] . After MAIM1 conjugation, the inhibitory effect of MCL-1∆N∆C on BID BH3 deuterium exchange was impaired, as evidenced by more rapid deuteration. Whereas one peptide subpopulation was initially protected (as in the presence of MCL-1∆N∆C), the other portion was rapidly deuterated, and complete exchange was restored by the 40-s time point ( Fig. 3) . These data indicate that MAIM1 derivatization of MCL-1∆N∆C drives the BH3 binding equilibrium to the unbound state.
The corresponding HXMS analysis was then performed on the MCL-1∆N∆C protein. We found that MAIM1 conjugation only minimally affected the deuterium-exchange profile of MCL-1∆N∆C, and subtle protection was evident in the MAIM1-binding region adjacent to the α3-α4 loop and the N terminus of α4 ( Fig. 4a,b) . In contrast, BID BH3 binding to MCL-1∆N∆C caused dramatic protection of the peptide regions composing the canonical groove, and lower-grade protection was transmitted to the α5-α6 loop and N-terminal region of α6, which contains C286 ( Fig. 4c,d) . However, after MAIM1 conjugation, the BH3-induced protective effects were notably reversed, thus again suggesting that MAIM1 derivatization impairs the BH3 binding capacity of MCL-1∆N∆C ( Fig. 4e) . We confirmed that this effect was dependent on C286, because exposure of MCL-1∆N∆C C286S to MAIM1 caused no change in the capacity of BID BH3 to protect MCL-1∆N∆C C286S from deuterium exchange (Supplementary Fig. 2 ).
To determine whether the observed effects of MAIM1 on the conformational dynamics of BH3 binding affected the functional activity of MCL-1∆N∆C, we tested the BAX-suppressive function of MCL-1∆N∆C in liposomal release assays. Whereas recombinant fulllength BAX had no effect on the integrity of liposomes preloaded with the ANTS-DPX fluorophore-quencher pair, the addition of truncated BID (tBID) directly triggered BAX membrane translocation npg a r t i c l e s and homo-oligomerization, thus leading to liposomal poration, as detected by dequenching of the ANTS fluorophore (Fig. 4f ). The addition of MCL-1∆N∆C to the mixture of tBID, BAX and liposomes blocked tBID-triggered, BAX-mediated liposomal release as a result of BH3 sequestration in the MCL-1∆N∆C groove. However, when MCL-1∆N∆C was preconjugated to MAIM1, the capacity to suppress tBID-induced BAX activation was impaired, and liposomal release ensued ( Fig. 4f) . Together, these data suggest a new allosteric mechanism for disrupting the BH3 binding functionality of MCL-1∆N∆C through covalent modification of C286 by MAIM1.
C286W mutation mimics MAIM1's allosteric inhibitory effect
To further validate an allosteric mechanism for MCL-1 inhibition, we performed C286W mutagenesis of MCL-1∆N∆C to simulate the 320-327 npg a r t i c l e s MAIM1 modification by installing tryptophan as a quinone mimetic 24 . FP binding analysis revealed that C286W mutagenesis shifted the FITC-BID BH3 and MCL-1∆N∆C binding isotherm to the right (Fig. 5a) , a result similar to that observed for MAIM1 derivatization of MCL-1∆N∆C (Fig. 2d) . In HXMS analyses, C286W mutagenesis likewise impaired the capacity of MCL-1∆N∆C, to suppress the deuterium exchange of BID BH3 over time, relative to the level of exchange observed after incubation with wild-type (WT) protein ( Fig. 5b  and Supplementary Fig. 3) . Whereas C286W mutagenesis itself had little to no effect on the baseline deuterium-exchange profile of MCL-1∆N∆C, the ability of added BID BH3 to decrease the level of deuterium exchange of canonical groove peptides was compromised by mutagenesis ( Fig. 5c) , as observed for MAIM1 derivatization ( Fig. 4a-e) . The functional effect of the observed changes in BH3 binding dynamics after C286W mutagenesis was evident in BAX-mediated liposomal release assays. In agreement with the negative effect of C286W mutagenesis on the binding interaction between FITC-BID BH3 and MCL-1∆N∆C, MCL-1∆N∆C C286W demonstrated impaired suppression of tBID-induced BAX activation, thereby resulting in liposomal release of the entrapped fluorophore ( Fig. 5d) . Thus, whether by small-molecule covalent modification of C286 or C286W mutagenesis, perturbation of this discrete region has a negative regulatory effect on the functional BH3 binding activity of MCL-1∆N∆C.
Cellular and mechanistic rationale for targeting MCL-1 C286
Given the recent successes in harnessing covalent bonding to cysteines for therapeutic development 15, 16, 25 , we sought to further validate a rationale for targeting the C286 region of MCL-1 by exploring the functional consequences of C286W mutagenesis in cells. Of note, we used our C286W mutagenic-mimicry approach for these cellular studies, rather than applying MAIM1, because the baseline electrophilic Michael acceptor and redox cycling properties of such quinones can cause nonspecific toxicity and consequently preclude their use in probing intracellular mechanisms 14 . Thus, we reconstituted Mcl1 −/− mouse embryonic fibroblasts (MEFs) 26 with WT or a C286W mutant form of human full-length MCL-1 ( Fig. 6a and Supplementary Data Set 1) and then subjected the cells to stress stimuli to evaluate viability responses. Mcl1 −/− MEFs reconstituted with the C286W-mutant, compared with cells reconstituted with WT MCL-1, showed a decreased survival advantage after serum withdrawal ( Fig. 6b and Supplementary Fig. 4 ) or treatment with cytochalasin D (Fig. 6c) . Correspondingly, Mcl1 −/− MEFs reconstituted with MCL-1 C286W demonstrated increased activation of caspases 3 and 7 (caspase 3/7) compared with cells reconstituted with WT MCL-1 ( Fig. 6d-f) , in agreement with a heightened apoptotic response to the stress stimuli, as also observed for Mcl1 −/− MEFs. We confirmed that the differential serum-withdrawal effects were independent of cell plating density ( Fig. 6g) and, importantly, Mcl1 −/− MEFs reconstituted with MCL-1 C286S were protected in a manner similar to that observed for Mcl1 −/− MEFs reconstituted with WT MCL-1 ( Supplementary Fig. 5 and Supplementary Data Set 1). These data highlight the selectivity of the tryptophan effect on MCL-1 function.
Interestingly, the mouse form of MCL-1 bears a phenylalanine at the position corresponding to C286 in the human protein (Supplementary Fig. 6 ) and maintains antiapoptotic functionality ( Fig. 6g) . Developmental compounds designed to target C286 would thus be expected to exhibit selectivity for human MCL-1 on the basis of this key compositional difference. Comparison of ligand-free and BH3-bound structures of mouse and human MCL-1 constructs revealed a similar orientation for F267 and C286 in the unbound form; however, there are notable differences in the disposition of these residues after BH3 engagement, and C286 is consistently solvent exposed across structures (Supplementary Fig. 6 ). From these observations, we anticipate that a much bulkier MAIM1-derivatized cysteine or tryptophan residue might negatively affect the capacity of the regional structure to accommodate the BH3 interaction.
To evaluate whether the impaired functional activity of MCL-1 C286W in cells could be linked to altered BH3 binding propensity, we npg a r t i c l e s used a biotinylated form of our selective stapled BH3-peptide inhibitor of MCL-1, biot-MCL-1 SAHB D 12 , in comparative streptavidin pulldown assays from lysates of Mcl1 −/− MEFs reconstituted with WT or C286W-mutant MCL-1. We found that MCL-1 SAHB D pulled down reconstituted MCL-1 C286W less efficiently than WT MCL-1 ( Supplementary Fig. 7 and Supplementary Data Set 1) . Together, the cellular data corroborated our in vitro findings and implicated specific alteration of the C286 region in the impairment of MCL-1's capacity to engage BH3 helices and suppress apoptosis.
To develop a conformational model of how C286 modification might disrupt the functional activity of MCL-1, we performed molecular dynamics (MD) simulations that assessed protein movements in the presence or absence of MAIM1 derivatization or C286W mutagenesis. The calculations suggested a common effect in decreasing the flexibility of MCL-1 protein in two discrete regions, including the otherwise mobile N terminus and, most intriguing, the region including α4 and portions of the adjacent α5 and α3 helices, which bridges the C286 region of α6 and the canonical groove at the opposite face of the protein (Fig. 7a-c and Supplementary Movies 1-3) . Interestingly, conformational flexibility of the canonical groove has been implicated in induced α-helical folding of BH3 domains and protein adaptation to maximize binding contacts with α-helical peptides and smallmolecule inhibitors 27, 28 . Whereas a shallow groove at the N-terminal face of proapoptotic BAX is more readily bound by a prefolded stapled α-helix, the deeper groove at the C-terminal pockets of BAX and other BCL-2 family proteins is capable of binding peptides that are otherwise linear in solution but fold after groove engagement [29] [30] [31] . Thus, a structurefunction model that incorporates our proteolysis, HXMS, MD and Mcl1 npg a r t i c l e s functional data would predict that MAIM1 derivatization and C286W mutagenesis rigidify the MCL-1 structure in a manner that alters proteolytic exposure, prevents conformational adaptation of the Cterminal groove to BH3 ligands and thereby decreases the BH3 binding efficiency and functional activity of MCL-1 (Fig. 7d) .
DISCUSSION
Pharmacologic targeting of MCL-1 holds promise to overcome the formidable apoptotic resistance of a broad range of human cancers. The successful strategy of neutralizing BCL-2 with ABT-199 is now being applied to MCL-1 (ref. 9), but the rapid turnover of MCL-1, along with its more complex biology, are potential roadblocks that will require continued exploration of diverse approaches for disarming MCL-1. In addition, controlling the degree of MCL-1 inhibition will be a critical factor, because mouse models of MCL-1 deletion have revealed severe physiologic consequences, including embryonic lethality, hematopoietic stem-cell loss, cardiomyopathy and mitochondrial dysfunction [32] [33] [34] [35] . The mostly normal phenotype of the corresponding heterozygotes suggests that partial or transient inhibition of MCL-1 may ultimately be required to avoid the toxic side effects of treatment.
Here, we found that modulation of MCL-1 at a new α6 regulatory site located on the opposite face of the protein from the canonical groove-the current focus of drug development-may provide an alternative approach for MCL-1 inhibition. The number of smallmolecule covalent inhibitors for cancer therapy is surging, and the capacity to harness cysteine residues for small-molecule drug discovery has become tractable 15, 16, 36 . Indeed, covalent allosteric inhibitors, compared with noncovalent orthosteric drugs, have the potential to deliver high-specificity targeting with improved toxicity profiles 37 .
Our HXMS studies indicate that alteration of the C286 region of MCL-1 allosterically impairs the capacity of the canonical groove to engage BH3 domains, thus resulting in functional suppression of the antiapoptotic binding activity implicated in oncogenesis and chemoresistance. Moreover, this mechanism appears to decrease MCL-1's BH3 binding efficiency rather than to block it entirely, a potentially desirable outcome given the toxicities associated with complete MCL-1 deletion. By shifting the BH3 binding equilibrium from a predominantly MCL-1-bound state to an unbound state, allosteric inhibitors of this noncanonical C286 site may provide a new opportunity for therapeutic targeting of MCL-1 in cancer. Indeed, simulating quinone derivatization of C286 by tryptophan mutagenesis impaired the capacity of MCL-1 to protect cells from apoptosis induction, thus further validating the potential utility of developing next-generation molecules for covalent modulation of MCL-1.
METHODS

Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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